‘Serious Risks to Women’: Over 20 Attorneys General Call for Regulation of Abortion Pill

‘[I]n the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria,’ the attorneys general wrote.

RFK Jr. Announces HHS Review of Organ Procurement After ‘Horrifying’ Revelations that Some Patients Were Still Alive

While organ donation can be a life-saving gift, malpractice and unethical practices jeopardize the dignity and right to life of donors.

FDA Will Conduct Investigation into Abortion Pill Following Blockbuster Study on Risks

The move follows the recent release of a new study finding that the serious adverse reaction rate associated with mifepristone is far higher than previously reported.